Clofazimine Inhibits Human Kv1.3 Potassium Channel by Perturbing Calcium Oscillation in T Lymphocytes
Author Information
Author(s): Ren Yunzhao R., Pan Fan, Parvez Suhel, Fleig Andrea, Chong Curtis R., Xu Jing, Dang Yongjun, Zhang Jin, Jiang Hongsi, Penner Reinhold, Liu Jun O.
Primary Institution: The Johns Hopkins University School of Medicine
Hypothesis
Clofazimine is a novel inhibitor of the human Kv1.3 potassium channel that affects calcium signaling in T lymphocytes.
Conclusion
Clofazimine effectively inhibits the Kv1.3 channel and alters calcium oscillation patterns, suggesting its potential as an immunomodulatory drug for autoimmune disorders.
Supporting Evidence
- Clofazimine was identified as a potent inhibitor of IL-2 production in Jurkat T cells.
- It inhibited Kv1.3 channel activity with an IC50 of 300 nM.
- Clofazimine disrupted calcium oscillation patterns in T cells.
- It was effective in preventing human T cell-mediated skin graft rejection in a mouse model.
- Clofazimine showed selectivity for Kv1.3 over other potassium channels.
Takeaway
Clofazimine is a drug that can help control how T cells work by blocking a specific channel, which might help treat diseases where the immune system is too active.
Methodology
The study involved screening a drug library to identify clofazimine as an inhibitor of Kv1.3, followed by various assays to assess its effects on calcium signaling and T cell activation.
Limitations
The study primarily focused on human T cells, and results may not directly translate to other species, particularly in vivo models.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website